Los Angeles Times feature: “Why the lack of diversity in drug industry leadership is hurting women and people of color,” written by Lindsay Androski, RSV CEO
RSV CEO Lindsay Androski celebrates a woman-led company that received FDA approval for a serious unmet need in women’s health, argues that more diverse leaders will increase industry focus on the needs of diverse patients, and talks about RSV’s efforts to address this issue through a first-of-its-kind program to train tomorrow’s diverse leaders in real-world drug development focused on unmet needs!
Stay tuned for another exciting announcement on that soon, as well as more details about RSV’s work to use existing technology to improve the lives of patients living with sickle cell disease.